|
|
|
| Effects of Fuzheng Huayu Capsule and Bifidotriple Viable Bacteria Assisted by Tenofovir on Liver Fibrosis in Elderly Patients with Hepatitis B Cirrhosis |
| XU Juan, LI Xiao-xue |
| Ankang Center for Disease Control and Preverntion,Ankang Shaanxi 725000 |
|
|
|
|
Abstract 【Objective】 To study the effect of Fuzheng Huayu Capsule and bifidobacterium triple viable bacteria combined with tenofovir on liver fibrosis and platelets in elderly patients with hepatitis B cirrhosis (HBC). 【Methods】 A total of 93 elderly HBC patients admitted to our hospital from April 2019 to April 2021 were selected as the research objects. Patients were divided into the Fuzheng Huayu group (31 cases), the viable bacteria group (31 cases) and The combined group (31 cases) by random number table method. The three groups were all given tenofovir. In addition, the Fuzheng Huayu group was given Fuzheng Huayu Capsules, the viable bacteria group was given bifidotriple viable bacteria, and the combination group was given Fuzheng Huayu Capsule + Bifidobacterium triple viable bacteria. The HBV DNA quantification (HBV-DNA), HBV-DNA negative convert rate, liver function indexes [alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)], liver fibrosis indicators [type Ⅲ procollagen (PC-Ⅲ), hyaluronic acid (HA), laminin (LN), type Ⅳ collagen (Ⅳ-C)] and serum inflammatory factors [tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), interleukin-8 (IL-8)] were compared among the three groups. 【Results】 After treatment, the levels of HBV-DNA in the three groups were lower than those before treatment. The HBV-DNA level in the combination group was lower than that in the bifidotriple viable bacteria group and the Fuzheng Huayu group. While the Fuzheng Huayu group was lower than the live bacteria group. The difference were statistically significant (P<0.05).The negative rate of HBV-DNA in the combined group (93.55%) was higher than that in the viable bacteria group (70.97%) and the Fuzheng Huayu group (64.52%) (P<0.05). After treatment, the three groups of HBV-DNA, TBIL, AST, ALT , Ⅳ-C, PC-Ⅲ, LN, HA, IL-8, TNF-α, hs-CRP, IL-6 levels were lower than those before treatment; And the combined group was lower than the viable bacteria group and the Fuzheng Huayu group (P<0.05). 【Conclusion】 Fuzheng Huayu Capsules and bifidobacterium triple viable bacteria combined with tenofovir have significant effects in the treatment of elderly HBC, which can improve liver function, inhibit liver fibrosis, improve blood coagulation function, and inhibit inflammatory symptoms of the body.
|
|
Received: 20 June 2022
|
|
|
|
|
|
[1] 赵可馨,徐光文,李楠,等.乙型肝炎病毒阳性肝硬化患者进展为肝细胞肝癌预测模型的建立及验证[J].中华检验医学杂志,2022,45(5):516-521.
[2] 王洁冰,唐平阳,徐会选,等.蚁利肝胶囊联合替诺福韦对乙肝肝硬化患者的肝功能及肝纤维化的影响[J].中国医药导报,2020,17(28):147-150.
[3] 张雯,彭琼.乙肝肝硬化患者肠道菌群与肝功能及血清炎症因子水平的关系[J].现代消化及介入诊疗,2020,25(2):158-162.
[4] 田琰,武胜,邓双双,等.扶正化瘀胶囊结合抗病毒药物治疗乙型肝炎肝硬化效果及对谷草转氨酶-血小板比值指数的影响[J].中华中医药学刊,2021,39(7):176-179.
[5] 中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].中国病毒病杂志,2015,31(12):1941-1960.
[6] 谢佳新,丁一波,张丽,等.乙肝病毒前S基因变异与乙肝肝硬化的相关性研究[J].实用预防医学,2020,27(5):547-550.
[7] 赵阳,李烨,赵臣,等.替诺福韦酯挽救抗病毒治疗失败的失代偿期乙型肝炎后肝硬化患者疗效分析[J].中国全科医学,2020,23(2):165-169.
[8] 刘丽波,王淑辉,段旭峰,等.肠道菌群失调与肝硬化伴SBP患者疾病发展的关系及三联活菌胶囊干预性研究[J].中国微生态学杂志,2021,33(9):1086-1089.
[9] 邓项俊,王威,朱圣涛,等.扶正化瘀胶囊联合微生态制剂和恩替卡韦治疗乙型肝炎病毒感染失代偿期肝硬化的临床研究[J].现代生物医学进展,2020,20(18):3553-3557.
[10] 刘雪冰,吴玉潇,刘谢,等.扶正化瘀胶囊对肝纤维化患者细胞因子的调控作用[J].中西医结合肝病杂志,2020,30(4):367-371.
[11] 李璐,胡冬青,孙建光,等.基于“祛邪为先”理念探讨中西医结合治疗乙型肝炎肝硬化思路和方法[J].山东中医杂志,2019,38(7):624-628.
[12] 刘姝,王飞.溃疡性结肠炎患者肠道菌群紊乱与Th17/Treg及其分泌炎性细胞因子免疫平衡的关系[J].现代医学,2020,48(7):862-867. |
|
|
|
2023, Vol. 40 
